Radionics Announces FDA Clearance for the Latest Version of its XKnife Stereotactic Radiotherapy Treatment Planning Software.

BURLINGTON, Mass.--(BW HealthWire)--Oct. 16, 1998--Today Radionics announced the FDA clearance of its XKnife Version 4.0 software for stereotactic radiation therapy treatment planning. This software is used for the development of radiotherapy treatment plans to treat lesions in the brain, including tumors and vascular malformations.

XKnife Version 4.0 represents the latest software version of the Radionics' XKnife Stereotactic Radiosurgery System, utilized to deliver a maximal dose of radiation to a target in the cranium while minimizing the dose to the surrounding tissue. The result of years of clinical experience, the XKnife Version 4.0 software uses the most advanced algorithms and graphics for 2D and 3D dose planning and evaluation. The software guides the user in a logical sequence from image acquisition to final treatment plan selection. Features of XKnife Version 4.0 include AutoPlan(R), used to optimize the radiation beams; and XJaws conformal arcs, which shape the radiation beams using equipment already on the linear accelerator.

"The XJaws feature in XKnife Version 4.0 enables the user to develop more conformal treatment plans, directing more of the radiation dose to the tumor and less to critical structures and normal tissue. The software's many new features make treatment planning easier for the clinician and the result is better for the patient," stated Charles Vecoli, Radionics' Product Manager for Radiation Therapy Products.

Radionics, the worldwide leader in stereotactic surgery, has been mapping the future of medical technology by producing innovative surgical devices since 1938. The company's products are being used successfully at 350+ sites worldwide. For more information, contact the Radionics Marketing department at [phone] or [phone].